Tocilizumab-coated solid lipid nanoparticles loaded with cannabidiol as a novel drug delivery strategy for treating COVID-19: A review

Frontiers in Immunology

Immunology

Marlena Szalata¹  Milena Szalata²  Jacek Karczewski³  Agnieszka Dobrowolska⁴  Piotr Eder⁴  Karolina Wielgus⁵  Atanas G. Atanasov⁶  Szymon Hryhorowicz⁷  Aleksandra Zielińska⁷  Ryszard Słomski⁷  Eliana B. Souto⁸ 

[1] Department of Biochemistry and Biotechnology, Poznań University of Life Sciences, Poznań, Poland;Department of Biotechnology, Institute of Natural Fibres and Medicinal Plants National Research Institute, Poznan, Poland;Department of Environmental Medicine/Department of Gastroenterology, Human Nutrition and Internal Medicine, Poznan University of Medical Sciences, Poznan, Poland;Department of Gastroenterology, Dietetics, and Internal Diseases, Poznan University of Medical Sciences, Poznan, Poland;Department of Pediatric Gastroenterology and Metabolic Diseases, Poznan University of Medical Sciences, Poznan, Poland;Institute of Genetics and Animal Biotechnology, Magdalenka, Poland;Institute of Neurobiology, Bulgarian Academy of Sciences, Sofia, Bulgaria;Department of Pharmacognosy, University of Vienna, Vienna, Austria;Institute of Human Genetics, Polish Academy of Sciences Poznan, Poznan, Poland;UCIBIO – Applied Molecular Biosciences Unit, MEDTECH, Laboratory of Pharmaceutical Technology, Department of Drug Sciences, Faculty of Pharmacy, University of Porto, Porto, Portugal;Associate Laboratory i4HB - Institute for Health and Bioeconomy, Faculty of Pharmacy, University of Porto, Porto, Portugal;

关键词: COVID-19;    solid lipid nanoparticles (SLN);    tocilizumab (TCZ);    cannabidiol (CBD);    cytokine storm;    oral drug therapy;   

DOI  :  10.3389/fimmu.2023.1147991

 received in 2023-01-19, accepted in 2023-03-06,  发布年份 2023

来源: Frontiers

【 摘 要 】

Commonly used clinical strategies against coronavirus disease 19 (COVID-19), including the potential role of monoclonal antibodies for site-specific targeted drug delivery, are discussed here. Solid lipid nanoparticles (SLN) tailored with tocilizumab (TCZ) and loading cannabidiol (CBD) are proposed for the treatment of COVID-19 by oral route. TCZ, as a humanized IgG1 monoclonal antibody and an interleukin-6 (IL-6) receptor agonist, can attenuate cytokine storm in patients infected with SARS-CoV-2. CBD (an anti-inflammatory cannabinoid and TCZ agonist) alleviates anxiety, schizophrenia, and depression. CBD, obtained from Cannabis sativa L., is known to modulate gene expression and inflammation and also shows anti-cancer and anti-inflammatory properties. It has also been recognized to modulate angiotensin-converting enzyme II (ACE2) expression in SARS-CoV-2 target tissues. It has already been proven that immunosuppressive drugs targeting the IL-6 receptor may ameliorate lethal inflammatory responses in COVID-19 patients. TCZ, as an immunosuppressive drug, is mainly used to treat rheumatoid arthritis, although several attempts have been made to use it in the active hyperinflammatory phase of COVID-19, with promising outcomes. TCZ is currently administered intravenously. It this review, we discuss the potential advances on the use of SLN for oral administration of TCZ-tailored CBD-loaded SLN, as an innovative platform for managing SARS-CoV-2 and related infections.

【 授权许可】

Unknown   
Copyright © 2023 Zielińska, Eder, Karczewski, Szalata, Hryhorowicz, Wielgus, Szalata, Dobrowolska, Atanasov, Słomski and Souto